Jeffrey Conklin
Adolescent Medicine · Ashburn, VANPI 1265513238
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $819 and has fallen 71.2% since, to $236 in 2025.
Across 130 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$550
- AbbVie$307
- Pfizer$245
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$186
- Abbott$151
- Genentech USA, Inc.$104
- plus $822 from 22 others
What the payments were for
- Food & beverage$2,365100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $550 |
| AbbVie(2 entities) | 14 | $307 |
| Pfizer | 12 | $245 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $186 |
| Abbott | 7 | $151 |
| Genentech USA, Inc. | 6 | $104 |
| Lilly USA, LLC | 6 | $80 |
| Amgen | 4 | $76 |
| AstraZeneca | 5 | $74 |
| Merck | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $46 |
| Clarus Therapeutics Inc. | 3 | $43 |
| GSK | 2 | $42 |
| Kaleo, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Exact Sciences | 1 | $28 |
| Novartis | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Optinose US, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $18 |
| Watermark Medical, Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
How this compares
$2,365 in reported general payments places this provider in the 75th percentile of 49 adolescent medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 52 | $77,535 |
| JanuviaSitagliptin Phosphate | 27 | $33,671 |
| JardianceEmpagliflozin | 11 | $19,716 |
| TrulicityDulaglutide | 15 | $18,758 |
| MounjaroTirzepatide | 11 | $11,006 |
| MyrbetriqMirabegron | 12 | $5,822 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $3,458 |
| Atorvastatin Calcium | 232 | $2,341 |
| Levothyroxine Sodium | 156 | $1,812 |
| SynthroidLevothyroxine Sodium | 21 | $1,792 |
| Rosuvastatin Calcium | 127 | $1,780 |
| Enalapril Maleate | 69 | $1,712 |
| Montelukast Sodium | 64 | $1,579 |
| Metoprolol Succinate | 67 | $1,176 |
| Silodosin | 11 | $1,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $245 | $77,53552 claims |
| MerckJanuvia | $57 | $33,67127 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $80 | $29,76426 claims |
| Boehringer IngelheimJardiance | $31 | $19,71611 claims |
| GSKBreo Ellipta | $42 | $3,45811 claims |
| AbbVieSynthroid | $307 | $1,79221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 49 adolescent medicine providers in Virginia.
Other adolescent medicine in Ashburn
- John ZacharyMidlothian$301K
- George BrightMidlothian$284K
- Robert ShayneChester$165K
- Kerri SteeleChester$164K
- Mark PolanshekChester$164K
- Kevin CampbellChester$164K
- Michele BurgetMidlothian$133K
- Alok RustogiPotomac Falls$9K
- Peter HeymanRichmond$3K
- Melani de SilvaRichmond$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.